[go: up one dir, main page]

MX2008012019A - Uso de un inhibidor de cinasa para el tratamiento de tumores resistentes particulares. - Google Patents

Uso de un inhibidor de cinasa para el tratamiento de tumores resistentes particulares.

Info

Publication number
MX2008012019A
MX2008012019A MX2008012019A MX2008012019A MX2008012019A MX 2008012019 A MX2008012019 A MX 2008012019A MX 2008012019 A MX2008012019 A MX 2008012019A MX 2008012019 A MX2008012019 A MX 2008012019A MX 2008012019 A MX2008012019 A MX 2008012019A
Authority
MX
Mexico
Prior art keywords
abl
compounds
resistant
treatment
atp
Prior art date
Application number
MX2008012019A
Other languages
English (en)
Inventor
Daniele Fancelli
Antonella Isacchi
Michele Modugno
Juergen Moll
Luisa Rusconi
Chiara Soncini
Rosita Lupi
Original Assignee
Nerviano Medical Sciences Srl
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nerviano Medical Sciences Srl filed Critical Nerviano Medical Sciences Srl
Publication of MX2008012019A publication Critical patent/MX2008012019A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4162—1,2-Diazoles condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

La presente invención se refiere a compuestos de bajo peso molecular, es decir, tetrahidropirrolo[3,4-c]pirazoles, que muestran una alta afinidad para el bolsillo ATP de tirosina cinasa ABL. Estos compuestos son de este modo, inhibidores de tirosina cinasa competitivos de ATP, que exhiben una potencia inhibidora significante también, y en particular, hacia los mutantes ABL T315I resistentes al inhibidor BCR-ABL. Los compuestos de la invención encuentran una aplicación útil en el tratamiento de enfermedades mediadas por ABL resistentes al inhibidor BCR-ABL, tales como leucemia mielogenosa crónica resistente a Imatinib. Además, la invención proporciona un método de selección para la identificación de compuestos capaces de enlazar el bolsillo de ATP de una proteína cinasa, en particular, de la cinasa ABL mutante T315I.
MX2008012019A 2006-03-30 2007-03-29 Uso de un inhibidor de cinasa para el tratamiento de tumores resistentes particulares. MX2008012019A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP06112023 2006-03-30
PCT/EP2007/053041 WO2007113212A2 (en) 2006-03-30 2007-03-29 Use of a kinase inhibitor for the treatment of particular resistant tumors

Publications (1)

Publication Number Publication Date
MX2008012019A true MX2008012019A (es) 2008-10-03

Family

ID=38191079

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2008012019A MX2008012019A (es) 2006-03-30 2007-03-29 Uso de un inhibidor de cinasa para el tratamiento de tumores resistentes particulares.

Country Status (13)

Country Link
US (1) US8084455B2 (es)
EP (1) EP2004180A2 (es)
JP (1) JP5274444B2 (es)
CN (1) CN101410108B (es)
AR (1) AR060149A1 (es)
AU (1) AU2007233784A1 (es)
BR (1) BRPI0710179A2 (es)
CA (1) CA2647186A1 (es)
CL (1) CL2007000904A1 (es)
EA (1) EA200870305A1 (es)
MX (1) MX2008012019A (es)
TW (1) TW200808311A (es)
WO (1) WO2007113212A2 (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2350803T3 (es) * 2006-11-03 2011-01-27 Nerviano Medical Sciences S.R.L. Procedimiento de administración de un compuesto antitumoral.
US20110129467A1 (en) * 2008-07-24 2011-06-02 Nerviano Medical Sciences S.R.L. Therapeutic combination comprising an aurora kinase inhibitor and antiproliferative agents
JP5738196B2 (ja) 2008-12-22 2015-06-17 ミレニアム ファーマシューティカルズ， インコーポレイテッドＭｉｌｌｅｎｎｉｕｍ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． オーロラキナーゼ阻害剤および抗ｃｄ２０抗体の併用
US8648078B2 (en) * 2009-07-29 2014-02-11 Nerviano Medical Sciences S.R.L. PLK inhibitor salts
GB2508652A (en) * 2012-12-07 2014-06-11 Agency Science Tech & Res Heterocyclic piperazine derivatives
CN103113355B (zh) * 2013-02-27 2014-08-13 无锡爱内特生物科技有限公司 一种Bcr/Abl酪氨酸激酶抑制剂及其制备方法和在治疗慢性粒细胞白血病中的应用
CN104072498B (zh) * 2013-03-26 2016-12-28 沈阳药科大学 （R）‑N‑[5‑(2‑甲氧基‑2‑苯基乙酰基)‑1,4,5,6‑四氢吡咯并[3,4‑c]吡唑‑3‑基]‑4‑(4‑甲基哌嗪‑1‑基)苯甲酰胺的合成方法
US10335494B2 (en) 2013-12-06 2019-07-02 Millennium Pharmaceuticals, Inc. Combination of aurora kinase inhibitors and anti-CD30 antibodies
CN105037399B (zh) * 2014-04-17 2017-04-26 深圳永泽医药股份有限公司 一类Bcr‑Abl双倍体抑制剂及制备方法与用途
US20180207173A1 (en) 2015-07-21 2018-07-26 Millennium Pharmaceuticals, Inc. Administration of aurora kinase inhibitor and chemotherapeutic agents
WO2019195658A1 (en) 2018-04-05 2019-10-10 Dana-Farber Cancer Institute, Inc. Sting levels as a biomarker for cancer immunotherapy
WO2021041532A1 (en) 2019-08-26 2021-03-04 Dana-Farber Cancer Institute, Inc. Use of heparin to promote type 1 interferon signaling

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7141568B2 (en) * 2003-07-09 2006-11-28 Pfizer Italia S.R.L. Pyrrolo[3,4-c]pyrazole derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them

Also Published As

Publication number Publication date
WO2007113212A2 (en) 2007-10-11
US8084455B2 (en) 2011-12-27
CL2007000904A1 (es) 2008-02-22
CA2647186A1 (en) 2007-10-11
EP2004180A2 (en) 2008-12-24
TW200808311A (en) 2008-02-16
AU2007233784A1 (en) 2007-10-11
BRPI0710179A2 (pt) 2011-08-09
AR060149A1 (es) 2008-05-28
EA200870305A1 (ru) 2009-02-27
US20100035876A1 (en) 2010-02-11
CN101410108B (zh) 2012-08-15
JP2009531386A (ja) 2009-09-03
WO2007113212A3 (en) 2008-01-24
CN101410108A (zh) 2009-04-15
JP5274444B2 (ja) 2013-08-28

Similar Documents

Publication Publication Date Title
MX2008012019A (es) Uso de un inhibidor de cinasa para el tratamiento de tumores resistentes particulares.
NO20082093L (no) Anvendelse av pyrazol [1,5-A]pyrimidinderivater for inhibering av proteinkinaser
TW200801008A (en) Protein kinase inhibitors
MX2010005950A (es) 2-fluoropirazolo[1,5-a]pirimidinas como inhibidores de proteina quinasa.
IL173348A0 (en) Thienopyridine and furopyridine kinase inhibitors
MXPA06010904A (es) Inhibidores de pirazol cinasa triciclicos.
MX2009005011A (es) Imidazopirazinas como inhibidores de proteina quinasa.
NO20081952L (no) Substituerte pyrazolforbindelser
TW200634010A (en) Pyrrolo[2,3-b]pyridin-4-yl-amines and pyrrolo[2,3-b]pyrimidin-4-yl-amines as janus kinase inhibitors
TW200745128A (en) Pyrazolopyrimidines as protein kinase inhibitors
MY149044A (en) Pyrazolopyrimidines - derivatives as cyclin dependent kinase inhibitors
WO2006004833A3 (en) Pyrrolotriazine kinase inhibitors
WO2008083367A3 (en) Polycyclic heteroaryl substituted triazoles useful as axl inhibitors
TW200745123A (en) Pyrazolopyrimidines as protein kinase inhibitors
DE602004024374D1 (de) Zusammensetzungen zur verwendung als protein-kinase-inhibitoren
WO2006050109A3 (en) Novel kinase inhibitors
MX2009013729A (es) Imidazopirazinas como inhibidores de proteina quinasa.
MX2009010284A (es) Inhibidores de la tirosina-cinasa de bruton.
MX2007001986A (es) Compuestos de aminoheteroarilo como inhibidores de proteina quinasa.
IL176233A0 (en) Organophosphorous indazole derivatives and use thereof as protein kinase inhibitors
MX2009003734A (es) Pirazolopirimidinas como inhibidor de cinasas dependientes de ciclina.
TW200745127A (en) Pyrazolopyrimidines as protein kinase inhibitors
MX2007003154A (es) Compuestos de diaminotriazol de utilidad como inhibidores de proteina quinasa.
MXPA05013076A (es) Compuestos de isoindolina-1-ona como inhibidores de cinasa.
MXPA05009151A (es) Inhibidores de cinasa heterociclica.